These results suggest that ARG1 and ROS production may play an important role in the suppressive function of LOX-1+PMN-MDSCs in (R/M) HNSCC patients undergoing immunotherapy. The gene discussed is ARG1; the disease is head and neck squamous cell carcinoma.